#lapatinib

Discover the brand name of Lapatinib and learn about its uses and benefits. Understand how this medication is utilized in medical treatments for specific health conditions.

Lapatinib Industry: Global Market Trends, Share, Size and Forecast Report 2018-2025

This report studies the global Lapatinib market status and forecast, categorizes the global Lapatinib market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

The major manufacturers covered in this report  Genentech Inc Novartis AG Pfizer Abnova…

Onlangs bleek al uit een studie dat nieuwe ‘wondermiddelen’ tegen kanker patiënten niet helpen om langer te leven of om hun kwaliteit van leven te verbeteren.

Nieuw onderzoek heeft nu ook aangetoond dat het kankermedicijn lapatinib juist kan leiden tot de groei van tumoren.

Lapatinib wordt in combinatie met andere kankermedicijnen en chemotherapie gebruikt om patiënten met een bepaalde soort borstkanker te behandelen.

Sneller groeien

Onderzoekers van onder andere het Francis Crick Institute in Londen hebben laten zien dat lapatinib ervoor kan zorgen dat borstkankercellen sneller groeien.

“Als bepaalde borstkankermedicijnen kankercellen in het laboratorium sneller doen groeien, moeten we kijken of dat mogelijk ook gebeurt bij patiënten,” zei hoofdonderzoeker Jeroen Claus.

Ongeveer een vijfde van alle borstkankers wordt veroorzaakt doordat een eiwit genaamd HER2 kankercellen het signaal geeft om te groeien en te delen.

Andere receptor

Lapatinib is één van de vele middelen die gebruikt worden om HER2 uit te schakelen zodat de cellen stoppen met groeien of afsterven.

De onderzoekers ontdekten dat het medicijn ervoor zorgt dat HER2 zich koppelt aan een andere receptor, HER3 geheten.

Krachtiger

Samen sturen ze vervolgens krachtige signalen naar de kankercellen om zich te vermenigvuldigen, krachtiger nog dan de signalen die worden gestuurd naar cellen die niet zijn behandeld met lapatinib.

Lapatinib Sales Market market share and growth rate forecast 2022

In this report, the global Lapatinib market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. View Entire Report @ https://www.reportsandmarkets.com/reports/global-lapatinib-sales-market-report-2017-1623060 Geographically, this report split global into several key Regions, with sales (K Pcs), revenue…

Meme kanserini 11 günde küçülten ilaç

İngiltere’de doktorlar, birlikte kullanılan iki ilacın bazı meme kanseri türlerini 11 günde küçültüp yok ettiğini gösterdi.

Avrupa Meme Kanseri Konferansı’nda duyurulan “sürpriz” bulguların, kadınların artık kemoterapiye ihtiyaç duymayacağı anlamına gelebileceği belirtiliyor.

257 kadın üzerinde denenen ilaçlar, her on meme kanserinden birinde görülen bir zayıflığı hedef alıyor.

Uzmanlar bu…

LAPATINIB

Title: Lapatinib CAS Registry Number: 231277-92-2 CAS Name: N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine Manufacturers’ Codes: GW-572016 Trademarks: Tykerb (GSK) Molecular Formula: C29H26ClFN4O4S Molecular Weight: 581.06 Percent Composition: C 59.94%, H 4.51%, Cl 6.10%, F 3.27%, N 9.64%, O 11.01%, S 5.52%

Lapa…

In this study, the addition of lapatinib was investigated in combination with the sequential use of both approaches TPF induction chemotherapy followed by chemoradiation in locally advanced larynx or hypopharynx squamous cell carcinoma.

Seven male patients were included. Three patients were included in the first cohort, at dose level 1 (LAP 500mg daily plus TPF). Renal toxicity was observed among these three patients with 1 dose-limiteng toxicity (DLT), leading to treatment interruption. In a second cohort of four patients administering docetaxel from the second cycle, 3 more DLTs were observed. Based on the occurrence of 4 DLTs at the first dose level of LAP, patient recruitment was closed.

These results again confirm a toxicity potential of induction protocol and indicate that lapatinib cannot be combined safely with full dose TPF.

  Article: http://www.docguide.com/eortc-24051-unexpected-side-effects-phase-i-study-tpf-induction-chemotherapy-followed-chemoradiation